In this study, the translocation of C/EBPβ in preadipocytes was inhibited by Cpn60 treatment, which subsequently decreased the expression of Pparg and C/EBPβ, demonstrating the potential of Cpn60 as a therapeutic molecule for obesity. Here, HSPD1 is linked to obesity disorder.